Aprocitentan is a dual endothelin A/B receptor (ETA/ETB) antagonist jointly developed and produced by Swiss company Idorsia and Johnson&Johnson. On March 19, 2024, Aprocitentan was approved for market by the US FDA. Aprocitentan is a novel oral antihypertensive drug that inhibits the binding of endothelin-1 (ET-1) to endothelin receptor A (ETA) and endothelin receptor B (ETB), blocking the harmful effects of endothelin-1 such as vasoconstriction, fibrosis, cell proliferation, and inflammation. Suitable for treating uncontrolled hypertension in patients with poor control of other treatments.
CAS NO.1103522-45-7
We can support intermediate,API and the technology transfer from starting material to api.Contact information:Mr.Xu19965424115.
Aprocitentan list of intermediates and impurities (for more information, please click directly)